Warning letter
Amplion Clinical Communications Inc: warning letter of Dec 17, 2013
FDA warning letter 416695 · New Orleans District Office
Key facts
| Reference number | 416695 |
|---|---|
| Company | Amplion Clinical Communications Inc |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | Dec 17, 2013 |
| Posted date | Dec 17, 2013 |
| Issuing office | New Orleans District Office |
| Product type | Devices |
| CFR sections cited | 803, 803.17, 820, 820.40 |
| Inspection city | Nashville |
| Inspection ZIP | 37211 |
| Inspection start date | Oct 28, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: